Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

NCT06901349 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06901349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06901349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Withdrawn
Start date
May 23, 2025
Completion date
June 10, 2025
Enrollment
0 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight